NCT03546842View on ClinicalTrials.gov

Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)

PHASE3CompletedINTERVENTIONAL

Enrollment

201

Participants

Timeline

Start Date

June 29, 2018

Primary Completion Date

January 29, 2019

Study Completion Date

January 29, 2019

Conditions

Papillomavirus InfectionsUterine Cervical NeoplasmsVulvar NeoplasmsVaginal NeoplasmsAdenocarcinoma in SituCondylomata Acuminata

Interventions

BIOLOGICAL

9vHPV vaccine

9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine in a 0.5-mL intramuscular injection

Trial Locations (1)

100000

National Institute of Hygiene and Epidemiology ( Site 0001), Hanoi

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03546842 - Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017) | Biotech Hunter | Biotech Hunter